Gyre Therapeutics announced the appointment of CEO Yue Xiong and veterans Maxwell Kirkby and Claire Weston to its board, effective August 1, 2026. This expansion of scientific and governance expertise is intended to bolster Gyre's cross-border drug development efforts and strengthen its clinical pipeline management.